Unknown

Dataset Information

0

Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.


ABSTRACT: A major factor hindering the exploration of adoptive immunotherapy in preclinical settings is the limited availability of tumor-reactive human T cells. Here we developed a humanized mouse model that permits large-scale production of human T cells expressing the engineered melanoma antigen MART-1-specific TCR. Humanized mice, made by transplantation of human fetal thymic tissue and CD34+ cells virally-transduced with HLA class I-restricted melanoma antigen (MART-1)-specific TCR gene, showed efficient development of MART-1-TCR+ human T cells with predominantly CD8+ cells. Importantly, MART-1-TCR+CD8+ T cells developing in these mice were capable of mounting antigen-specific responses in vivo, as evidenced by their proliferation, phenotypic conversion and IFN-? production following MART-1 peptide immunization. Moreover, these MART-1-TCR+CD8+ T cells mediated efficient killing of melanoma cells in an HLA/antigen-dependent manner. Adoptive transfer of in vitro expanded MART-1-TCR+CD8+ T cells induced potent antitumor responses that were further enhanced by IL-15 treatment in melanoma-bearing recipients. Finally, a short incubation of MART-1-specific T cells with rapamycin acted synergistically with IL-15, leading to significantly improved tumor-free survival in recipients with metastatic melanoma. These data demonstrate the practicality of using humanized mice to produce potentially unlimited source of tumor-specific human T cells for experimental and preclinical exploration of cancer immunotherapy. This study also suggests that pretreatment of tumor-reactive T cells with rapamycin in combination with IL-15 administration may be a novel strategy to improve the efficacy of adoptive T cell therapy.

SUBMITTER: Hu Z 

PROVIDER: S-EPMC4872726 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.

Hu Zheng Z   Xia Jinxing J   Fan Wei W   Wargo Jennifer J   Yang Yong-Guang YG  

Oncotarget 20160201 6


A major factor hindering the exploration of adoptive immunotherapy in preclinical settings is the limited availability of tumor-reactive human T cells. Here we developed a humanized mouse model that permits large-scale production of human T cells expressing the engineered melanoma antigen MART-1-specific TCR. Humanized mice, made by transplantation of human fetal thymic tissue and CD34+ cells virally-transduced with HLA class I-restricted melanoma antigen (MART-1)-specific TCR gene, showed effic  ...[more]

Similar Datasets

| S-EPMC5958800 | biostudies-literature
| S-EPMC5006579 | biostudies-literature
| S-EPMC10702851 | biostudies-literature
| S-EPMC1557589 | biostudies-literature
| S-EPMC4476714 | biostudies-literature
| S-EPMC4472313 | biostudies-literature
| S-EPMC4276906 | biostudies-literature
| S-EPMC7864867 | biostudies-literature
| S-EPMC6286512 | biostudies-literature
| S-EPMC4123131 | biostudies-literature